This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT501 administered subcutaneously to participants with Rheumatoid Arthritis (RA).
18 to 75 years old
Diagnosis of adult-onset RA for at least 6 months
Moderately to severely active RA
Inadequate treatment response as defined in the protocol
Functional class IV as defined by the ACR Classification of Functional Status in RA
Presence of any concomitant autoimmune disease other than RA
Active infection, history of serious recurrent or chronic infection
History of progressive multifocal leukoencephalopathy